CYTOKINETICS INC
CYTK evidence brief
What we can confirm
- BioSniper Score:
- 1.0 / 10
- Market Cap:
- $10.48B
What it means
What to watch
Prepared research question
What matters most for CYTK—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · CYTK
Cytokinetics is a biopharmaceutical company focused on developing small-molecule cardiac muscle myosin inhibitors for cardiovascular diseases, with one approved product (MYQORZO/aficamten) for obstructive hypertrophic cardiomyopathy and a pipeline of candidates for heart failure.
Key risk: Profitability uncertainty
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Market Cap
$10.48B
Cash Runway
—
Lead Asset
—
Next Catalyst
—
Financial data as of Jun 30, 2026.
Tracking 16 clinical trials · 1 FDA decision for CYTOKINETICS INC.
Cytokinetics is a biopharmaceutical company focused on developing small-molecule cardiac muscle myosin inhibitors for cardiovascular diseases, with one approved product (MYQORZO/aficamten) for obstructive hypertrophic cardiomyopathy and a pipeline of candidates for heart failure.
- MYQORZO (aficamten) was approved by the FDA in December 2025 for adults with obstructive HCM and by the European Commission in February 2026 [sec_mda · as of 2026-08-06].
- Net product revenue from MYQORZO was $25 million in Q2 2026 [news · published 2026-08-06].
- Cash, cash equivalents and investments totaled ~$1.7 billion as of June 30, 2026 [news · published 2026-08-06].
- The company reported a net loss of -$198.8M and an accumulated deficit of ~$3.9 billion since inception [latest reported financials as of 2026-06-30; sec_mda · as of 2026-08-06].
- Pipeline includes omecamtiv mecarbil (COMET-HF), CK-586 (AMBER-HFpEF), and CK-089 (Phase 1) [sec · filed 2026-04-17].
What works
- MYQORZO is approved in the U.S., EU, and China, providing a diversified commercial base [sec_mda · as of 2026-08-06].
- Strong cash position of ~$1.7 billion as of June 30, 2026 provides runway for commercialization and pipeline development [news · published 2026-08-06].
- Multiple pipeline programs target large cardiovascular indications, including heart failure (omecamtiv mecarbil, CK-586) [sec · filed 2026-04-17].
What to weigh
- The company has an accumulated deficit of ~$3.9 billion and no assurance of attaining profitability [sec_mda · as of 2026-08-06].
- Net income was -$198.8M for the period ending June 30, 2026, and shareholders' equity is negative (-$173.5M) [latest reported financials as of 2026-06-30].
- MYQORZO revenue is early-stage and uncertain; the company warns that there can be no assurance as to the timing or level of revenues [sec_mda · as of 2026-08-06].
- Total debt of $275.6M and reliance on additional capital if MYQORZO revenues are insufficient [latest reported financials as of 2026-06-30; sec_mda · as of 2026-08-06].
From the filings
Quoted directly from source documents.
MYQORZO FDA approval date
“the FDA approved in December 2025”
SEC MD&A · August 6, 2026
MYQORZO net product revenue Q2 2026
“MYQORZO® (aficamten) Net Product Revenue of $25 Million”
News · August 6, 2026
Cash position as of June 30, 2026
“~$1.7 Billion in Cash, Cash Equivalents and Investments as of June 30, 2026”
News · August 6, 2026
Accumulated deficit since inception
“We have incurred an accumulated deficit of approximately $3.9 billion since inception”
SEC MD&A · August 6, 2026
Risks & what to watch (4)›
Key risks
- Profitability uncertainty — Accumulated deficit ~$3.9B; no assurance of attaining profitability [sec_mda · as of 2026-08-06]
- Early commercial revenue — MYQORZO revenue is early and uncertain; company warns no assurance on timing or level [sec_mda · as of 2026-08-06]
- Negative equity and net loss — Shareholders' equity -$173.5M, net income -$198.8M as of 2026-06-30 [latest reported financials]
- Debt and capital needs — Total debt $275.6M; may need additional capital if MYQORZO revenues insufficient [latest reported financials; sec_mda]
What to watch
- Supplemental NDA for aficamten in non-obstructive HCM expected in Q4 2026 [news · published 2026-08-06].
- Topline results from ACACIA-HCM (aficamten in non-obstructive HCM) expected in Q2 2026 [news · published 2026-02-24].
- COMET-HF site activation and enrollment progress for omecamtiv mecarbil [sec · filed 2026-04-17].
- Regulatory review of MYQORZO in Canada, Switzerland, Hong Kong, and Taiwan [news · published 2026-08-06].
Sources: Catalysts · News · SEC filings · SEC MD&A · Generated October 6, 2026 · How we verify sources →
Run CYTOKINETICS INC through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available CYTOKINETICS INC facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 2 of 6 signals · derived from public data
Pipeline inputs are unavailable for this score. It uses only the available signals shown below.
Cash runway data unavailable
Net income -$199M
No tracked pipeline phase
No tracked pipeline candidates
No upcoming catalysts tracked
0 buys · 31 sells (180d)
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
438
Total value held
$8.29B
| Holder | Shares | Value |
|---|---|---|
| blackrock, inc. | 16,548,011 | $1.09B |
| fmr llc | 10,723,140 | $706.8M |
| wellington management group llp | 8,009,489 | $527.9M |
| vanguard portfolio management llc | 5,843,782 | $385.2M |
| state street corp | 5,745,193 | $378.7M |
| vanguard capital management llc | 5,488,634 | $361.8M |
| avoro capital advisors llc | 3,333,333 | $219.7M |
| geode capital management, llc | 3,215,415 | $212.0M |
| bank of america corp /de/ | 3,125,436 | $206.0M |
| rtw investments, lp | 2,721,158 | $179.4M |
Showing top 10 of 438 institutional holders of CYTOKINETICS INC. Open the full 13F history after sign-in.
Short Interest
as of May 20, 2026- % of float
- 20.8%
- Days to cover
- 9.3
- Shares short
- 15,896,196
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
CYTK short interestGovernance
Frequently asked questions
What is the AI investment thesis for CYTOKINETICS INC?
Cytokinetics is a biopharmaceutical company focused on developing small-molecule cardiac muscle myosin inhibitors for cardiovascular diseases, with one approved product (MYQORZO/aficamten) for obstructive hypertrophic cardiomyopathy and a pipeline of candidates for heart failure.
Who is the CEO of CYTOKINETICS INC?
Mr. Robert I. Blum is the chief executive officer of CYTOKINETICS INC (CYTK).
Where is CYTOKINETICS INC headquartered?
CYTOKINETICS INC (CYTK) is headquartered in South San Francisco, CA, United States.
What therapeutic areas does CYTOKINETICS INC focus on?
CYTOKINETICS INC develops therapies across Cardiovascular, Infectious Disease, Respiratory.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.